Concepedia

Author

David M. O’Malley

The Ohio State UniversityORCID

Also Known As

D M O'Malley, D O'Malley, D O'malley, D OMALLEY, D O’Malley, D O’malley, D. M. O'MALLEY, D. M. O'Malley, D. M. O'malley, D. M. O’Malley

879

Publications

30.9K

Citations

87

H-Index

217

Concepts

All Affiliations

The Ohio State UniversityThe Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research InstituteMemorial Sloan Kettering Cancer CenterThe University of Texas MD Anderson Cancer CenterThe Ohio State University Wexner Medical Center
DM

About

David M. O’Malley is an author at The Ohio State University specializing in medicine, obstetrics, and oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

57

169

16.8K

2

Natural Sciences

21

25

1.8K

3

Health Sciences

13

16

901

4

Engineering

11

11

1.3K

5

Nursing

2

2

77

David M. O’Malley

×

272

Publications

25.6K

Citations

83

H-Index

YearCitations

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

Éric Pujade-Lauraine, Jonathan A. Ledermann, Frédèric Selle,

The Lancet Oncology

2017

1.8K

Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial

Robert L. Coleman, Amit M. Oza, Domenica Lorusso,

The Lancet

2017

1.7K

Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial

Elizabeth M. Swisher, Kevin Lin, Amit M. Oza,

The Lancet Oncology

2016

1.2K

Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology

Deborah K. Armstrong, Ronald D. Alvarez, Jamie N. Bakkum‐Gamez,

Journal of the National Comprehensive Cancer Network

2021

688

Bevacizumab and paclitaxel–carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial

Robert L. Coleman, Mark F. Brady, Thomas J. Herzog,

The Lancet Oncology

2017

585

Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu

Amanda N. Fader, Dana M. Roque, Eric R. Siegel,

Journal of Clinical Oncology

2018

509

Pembrolizumab in Patients With Microsatellite Instability–High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study

David M. O’Malley, Giovanni M. Bariani, Philippe A. Cassier,

Journal of Clinical Oncology

2022

457

Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer

Daniela Matei, Virginia L. Filiaci, Marcus E. Randall,

New England Journal of Medicine

2019

444

<i>BRCA</i> Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma

Kevin Lin, Maria I. Harrell, Amit M. Oza,

Cancer Discovery

2018

403

Secondary Somatic Mutations Restoring <i>RAD51C</i> and <i>RAD51D</i> Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma

Olga Kondrashova, Minh Nguyen, Kristy Shield‐Artin,

Cancer Discovery

2017

396

Page 1